Denali (DNLI) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

$3.6M

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$127.6M

Net income growth (year over year)

−2.77%

Net margin

—

Return on equity

−54.93%

EPS (trailing twelve months)

−$2.84

Book value per share

$5.23

P/E (trailing twelve months)

—

Price to book

3.41

Debt to assets

27.87%

Payout ratio

—

Dividend yield

—

Company profile

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

• How do I buy stock in Denali (DNLI)?

  DNLI trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.